Bortezomib-induced histiocytoid Sweet syndrome.
Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma, has been reported to be associated with Sweet syndrome. However, careful review of the histopathology of the first reported case and our case revealed similar histologic and immunohistochemical findings (a mononuclear dermal infiltrate) and not the usual neutrophilic infiltrate of Sweet syndrome. We suggest that the dermatitis induced by bortezomib is best classified as "histiocytoid Sweet syndrome."
Murase
Jenny E
JE
Department of Dermatology, University of California, San Francisco, California, USA. jemurase@gmail.com
Wu
Jashin J
JJ
Theate
Ivan
I
Cole
Gary W
GW
Barr
Ronald J
RJ
Dyson
Senait W
SW
D000368:Aged; D001706:Biopsy; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D003875:Drug Eruptions / Q000473:pathology*; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000009:adverse effects*; D011719:Pyrazines / Q000009:adverse effects*; D016463:Sweet Syndrome / Q000139:chemically induced* / Q000473:pathology*
D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib